A preclinical xenograft model of prostate cancer using human tumors

被引：0

作者：

Mitchell G Lawrence

Renea A Taylor

Roxanne Toivanen

John Pedersen

Sam Norden

David W Pook

Mark Frydenberg

Melissa M Papargiris

Birunthi Niranjan

Michelle G Richards

Hong Wang

Anne T Collins

Norman J Maitland

Gail P Risbridger

机构：

[1] Monash University,Department of Anatomy and Developmental Biology

[2] Clayton,Department of Physiology

[3] Victoria,Department of Surgery

[4] Australia.,Department of Biology

[5] Monash University,undefined

[6] Clayton,undefined

[7] Victoria,undefined

[8] Australia.,undefined

[9] TissuPath Pathology,undefined

[10] Mount Waverley,undefined

[11] Victoria,undefined

[12] Australia.,undefined

[13] Monash University,undefined

[14] Clayton,undefined

[15] Victoria,undefined

[16] Australia.,undefined

[17] Victorian Node,undefined

[18] Monash University,undefined

[19] Clayton,undefined

[20] Victoria,undefined

[21] Australia.,undefined

[22] Yorkshire Cancer Research (YCR) Cancer Research Unit,undefined

[23] University of York,undefined

来源：

Nature Protocols | 2013年 / 8卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.

引用

页码：836 / 848

页数：12

共 74 条

[1]

Toivanen R(2012)Breaking through a roadblock in prostate cancer research: an update on human model systems J. Steroid Biochem. Mol. Biol. 131 122-131

[2]

Taylor RA(2011)Prostate cancer stem cells: do they have a basal or luminal phenotype? Horm. Cancer 2 47-61

[3]

Pook DW(1997)Stromal-epithelial interactions in the normal and neoplastic prostate Br. J. Urol. 79 18-26

[4]

Ellem SJ(1972)Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation Anat. Rec. 172 179-195

[5]

Risbridger GP(2011)Purification and direct transformation of epithelial progenitor cells from primary human prostate Nat. Protoc. 6 656-667

[6]

Maitland NJ(2010)Isolation, cultivation and characterization of adult murine prostate stem cells Nat. Protoc. 5 702-713

[7]

Frame FM(2006)Formation of human prostate tissue from embryonic stem cells Nat. Methods 3 179-181

[8]

Polson ES(2009)Lineage enforcement by inductive mesenchyme on adult epithelial stem cells across developmental germ layers Stem Cells 27 3032-3042

[9]

Lewis JL(2011)Brief report: a bioassay to identify primary human prostate cancer repopulating cells Stem Cells 29 1310-1314

[10]

Collins AT(2001)Identification and isolation of human prostate epithelial stem cells based on α(2)β(1)-integrin expression J. Cell Sci. 114 3865-3872

← 1 2 3 4 5 6 7 8 →